STRYKER CORP

Stryker Corporation reported strong financial results for the second quarter and first six months of 2026. For Q2 2026, net sales increased 9.4% to $6.59 billion, net earnings surged 44.3% to $1.28 billion, and diluted EPS grew 44.1% to $3.30. The company also completed the acquisition of Amplitude Vascular Systems (AVS) for $435 million in cash and potential milestone payments, and repaid $1.0 billion in senior unsecured notes.

Stryker reported strong second quarter 2026 operating results, with reported net sales increasing 9.4% to $6.6 billion and organic net sales growing 9.0%. Adjusted diluted EPS rose 17.9% to $3.69. The company's CEO, Kevin A. Lobo, highlighted significant progress in recovery from a cyber incident and expressed confidence in future growth. Stryker also narrowed its full-year 2026 guidance, now expecting organic net sales growth of 8.3% to 9.3% and adjusted net earnings per diluted share in the range of $14.95 to $15.10.

Stryker Corporation announced a change in its organizational structure in Q1 2026, creating a new Ortho Tech business by combining its orthopaedic instruments portfolio with Mako and other enabling technologies. This reorganization aims to simplify the customer experience and increase speed to market through focused innovation. Following this, Stryker will continue to have two reportable segments: MedSurg and Neurotechnology, and Orthopaedics. The company has recast its consolidated financial statements for the three years ended December 31, 2025, to reflect these segment reporting changes, which is for informational purposes and not a restatement of prior financials.

Stryker Corporation announced that William E. Berry, Jr. will retire from his role as Vice President, Chief Accounting Officer, effective September 1, 2026. Emily Baculik, currently Vice President, Corporate Controller, will succeed him as Chief Accounting Officer on the same date. Mr. Berry will transition to an Advisor to the Chief Financial Officer role until August 15, 2027, maintaining his current base salary of $510,000. Ms. Baculik's compensation will include an increased annualized base salary of $420,000 and a bonus target of 45% of her base salary, along with a recommendation for future equity awards.

Stryker announced the acquisition of Amplitude Vascular Systems (AVS) for $435 million in cash, with potential future milestone payments up to $400 million, to enhance its Vascular business. For the first quarter of 2026, the company reported a 2.6% increase in net sales to $6,020 million and a 13.9% rise in net earnings to $745 million, resulting in diluted EPS of $1.93. The company also repaid $1,000 million in senior unsecured notes and reorganized its Orthopaedics segment to create the new Ortho Tech business, while also noting a cybersecurity incident in Q1 2026.

Stryker's Board of Directors has declared a quarterly dividend of $0.88 per share. This dividend is payable on July 31, 2026, to shareholders of record at the close of business on June 30, 2026. The declared dividend reflects a 4.8% increase compared to the prior year, while remaining consistent with the previous quarter's payout.

Stryker Corporation reported Q1 2026 operating results with net sales increasing 2.6% to $6.0 billion and reported diluted EPS rising 14.2% to $1.93. Adjusted diluted EPS decreased 8.5% to $2.60, and adjusted operating income margin contracted by 180 bps to 21.1%. The company maintained its full-year 2026 guidance for organic net sales growth (8.0%-9.5%) and adjusted EPS ($14.90-$15.10), citing strong underlying business momentum and recovery from a cyber incident. Stryker also announced a new Ortho Tech business to streamline its orthopaedic portfolio.

Stryker (NYSE:SYK) announced a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company. AVS specializes in a next-generation intravascular lithotripsy (IVL) platform designed to treat calcified peripheral arterial disease. This acquisition is expected to strengthen Stryker's Peripheral Vascular portfolio and expand its presence in arterial disease treatment, complementing existing offerings once regulatory clearance is obtained.